Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
RiskBenefit Assessment and Pharmacovigilance Needs Given the widespread use of GLP-1RAs and other incretin-based agents for obesity and T2D, comprehensive evaluation of even common GI adverse effects remains limited
Under $10
But look at the rest of the timeline: it stops, and it grows back
Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)
US$ 29.82
US$ 25.42
US$ 22.38
US$ 22.47
